文献速递泌尿男性生殖肿瘤

恩扎卢胺对比恩扎卢胺联合阿比特龙治疗转移性去势抵抗性前列腺癌的随机III期研究(Alliance A031201试验)

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
PubMed 文献 · J Clin Oncol · 2023-03-30

这项随机III期研究将1311例未经治疗的转移性去势抵抗性前列腺癌患者按1:1随机分配至一线恩扎卢胺或恩扎卢胺联合阿比特龙醋酸酯及泼尼松(AAP)组,主要终点总生存(OS)在两组间无统计学差异(中位OS 32.7个月 vs 34.2个月,HR 0.89,单侧P=0.03,边界名义显著性水平=0.02)。影像学无进展生存(rPFS)在联合组更长(中位21.3个月 vs 24.3个月,HR 0.86,双侧P=0.02)。联合用药时阿比特龙的药代动力学清除率较单用阿比特龙高2.2至2.9倍。

要点

  • 恩扎卢胺联合AAP一线治疗mCRPC未在OS上显示统计学显著获益(HR 0.89,单侧P=0.03,未达边界0.02)。
  • 联合组rPFS更长(中位24.3个月 vs 21.3个月,HR 0.86,双侧P=0.02)。
  • 联合用药时阿比特龙清除率较单用阿比特龙高2.2至2.9倍,且联合方案非血液学毒性更多。

核心结论

  • 在mCRPC一线治疗中,恩扎卢胺联合AAP与恩扎卢胺单药相比,OS无统计学显著获益。
  • 两药间药物相互作用导致阿比特龙清除率增加,可能部分解释该结果,但并未阻止联合方案出现更多非血液学毒性。

研究设计与样本

  • 随机III期研究,纳入未经治疗的mCRPC男性患者,按1:1随机分配至一线恩扎卢胺联合或不联合AAP组。
  • 共1311例患者被随机分配:657例至恩扎卢胺组,654例至恩扎卢胺联合AAP组。
  • 主要终点为OS,同时评估毒性、前列腺特异性抗原下降、药代动力学和rPFS,采用意向性治疗分析。

主要发现

  • OS在两组间无统计学差异:恩扎卢胺组中位OS为32.7个月(95%CI 30.5至35.4),恩扎卢胺联合AAP组为34.2个月(95%CI 31.4至37.3),HR 0.89,单侧P=0.03,边界名义显著性水平=0.02。
  • rPFS在联合组更长:恩扎卢胺组中位rPFS为21.3个月(95%CI 19.4至22.9),恩扎卢胺联合AAP组为24.3个月(95%CI 22.3至26.7),HR 0.86,双侧P=0.02。
  • 联合用药时阿比特龙的药代动力学清除率较单用阿比特龙时高2.2至2.9倍。
  • 联合方案非血液学毒性更多。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other. We sought to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. PATIENTS AND METHODS: Men with untreated mCRPC were randomly assigned (1:1) to receive first-line enzalutamide with or without AAP. The primary end point was OS. Toxicity, prostate-specific antigen declines, pharmacokinetics, and radiographic progression-free survival (rPFS) were also examined. Data were analyzed using an intent-to-treat approach. The Kaplan-Meier estimate and the stratified log-rank statistic were used to compare OS between treatments. RESULTS: In total, 1,311 patients were randomly assigned: 657 to enzalutamide and 654 to enzalutamide plus AAP. OS was not statistically different between the two arms (median, 32.7 [95% CI, 30.5 to 35.4] months for enzalutamide v 34.2 [95% CI, 31.4 to 37.3] months for enzalutamide and AAP; hazard ratio [HR], 0.89; one-sided P = .03; boundary nominal significance level = .02). rPFS was longer in the combination arm (median rPFS, 21.3 [95% CI, 19.4 to 22.9] months for enzalutamide v 24.3 [95% CI, 22.3 to 26.7] months for enzalutamide and AAP; HR, 0.86; two-sided P = .02). However, pharmacokinetic clearance of abiraterone was 2.2- to 2.9-fold higher when administered with enzalutamide, compared with clearance values for abiraterone alone. CONCLUSION: The addition of AAP to enzalutamide for first-line treatment of mCRPC was not associated with a statistically significant benefit in OS. Drug-drug interactions between the two agents resulting in increased abiraterone clearance may partly account for this result, although these interactions did not prevent the combination regimen from having more nonhematologic toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Morris MJ, Heller G, Hillman DW, et al. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023. PMID: 36996380. doi:10.1200/JCO.22.02394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。